BeOne Medicines (NASDAQ:ONC) Stock Price Target Raised at Royal Bank Of Canada

BeOne Medicines (NASDAQ:ONC) had its target price boosted by Royal Bank Of Canada from $459.00 to $465.00 in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other research firms have also weighed in on ONC. Weiss Ratings upgraded shares of BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. JPMorgan Chase & Co. raised their price objective on BeOne Medicines from $425.00 to $445.00 and gave the company an “overweight” rating in a research report on Thursday, October 1st. Nomura raised their price objective on BeOne Medicines from $454.75 to $484.91 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Truist Financial restated a “buy” rating and set a $448.00 price objective (up from $420.00) on shares of BeOne Medicines in a research note on Friday. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $434.79.

BeOne Medicines Trading Up 5.1%

NASDAQ ONC traded up $19.71 during mid-day trading on Friday, hitting $406.96. The company’s stock had a trading volume of 941,725 shares, compared to its average volume of 364,122. The firm has a market capitalization of $44.68 billion, a P/E ratio of 51.71 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $410.71. The stock’s fifty day simple moving average is $363.49 and its two-hundred day simple moving average is $326.34.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.34 by $1.30. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.76 billion. Research analysts expect that BeOne Medicines will post 8.99 EPS for the current year.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 54,892 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total transaction of $19,659,569.80. Following the transaction, the chief executive officer owned 240,743 shares of the company’s stock, valued at $86,222,105.45. This trade represents a 18.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Chan Lee sold 1,115 shares of the firm’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $375.00, for a total value of $418,125.00. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 376,373 shares of company stock worth $134,848,154 over the last ninety days. Company insiders own 6.19% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. First Trust Advisors LP raised its position in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares during the period. Jennison Associates LLC boosted its position in BeOne Medicines by 102.1% during the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock valued at $45,871,000 after purchasing an additional 78,027 shares during the period. Renaissance Technologies LLC bought a new position in BeOne Medicines during the 1st quarter worth $19,438,000. Candriam S.C.A. grew its stake in BeOne Medicines by 31.7% during the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after buying an additional 62,470 shares during the last quarter. Finally, SEB Asset Management AB bought a new position in BeOne Medicines during the 1st quarter worth $16,653,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

BeOne Medicines Company Profile

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.